psychosis symptoms due to Shisheh. Other stimulant related disorders
Conditions
Interventions
Intervention 1: Patients will receive risperidone from Sobhan company daily in the therapeutic range of 2 to 8 mg. The patient will be evaluated by demographic questionnaire, urine test, PANSS positiv
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Having criteria for glass-induced psychosis disorder based on DSM-5 (through clinical interview by psychiatrist). Treated with one of the antipsychotics risperidone, quetiapine and olanzapine No other psychiatric disorders Willingness of an individual or family (conscious consent) to participate in the study Minimum age 18 If you have a history of drug treatment for the above disorder, at least three weeks have passed since you stopped taking the drug
Exclusion criteria
Exclusion criteria: History of mental disorders History of epilepsy History of brain trauma Taking drugs other than target group treatment drugs Unwillingness of the patient or the family to continue cooperating in the study for any reason Incomplete questionnaires If a sample has other psychiatric disorders, including personality disorders, it will be excluded from the plan and will continue its routine treatment. Incidence of drug complications based on the AIMS scale
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive Symptoms Severity. Timepoint: Before the intervention, one month after the intervention. Method of measurement: PANSS positive and negative symptom scale.;Negative Symptoms Severity. Timepoint: Before the intervention, one month after the intervention. Method of measurement: PANSS positive and negative symptom scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArash Mohagheghi
Tabriz University of Medical Sciences
Outcome results
None listed